Prolonged exposure of colon cancer cell to the epidermal growth factor receptor inhibitor gefitinib (Iressa™) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects

Amilia Azzariti, Letizia Porcelli, Jian Ming Xu, Grazia Maria Simone, Angelo Paradiso

Research output: Contribution to journalArticle

Abstract

Aim: To analyze the biological effects of prolonged in Vitro exposure of HT-29 and LoVo colon cancer cell lines to gefitinib (Iressal™), an inhibitor of epidermal growth factor receptor (EGFR) activity, and ZD6474, an inhibitor of both KDR and EGFR activities. Methods: Cells were treated with each drug for up to 2 wk using either a continuous or an intermittent (4 d of drug exposure followed by 3 d of washout each week) schedule. Results: In both cell types, prolonged exposure (up to 14 d) to gefitinib or ZD6474 produced a similar inhibition of cell growth that was persistent and independent of the treatment schedule. The effects on cell growth were associated with a pronounced inhibition of p-EGFR and/ or p-KDR expression. Treatment with gefitinib or ZD6474 also inhibited the expression of EGFR downstream signal molecules, p-Erkl/2 and p-Akt, although the magnitude of these effects varied between treatments and cell lines. Furthermore, expression of the drug resistance-related protein ABCG2 was shown to significantly increase after 14 d of continuous exposure to the two drugs. Conclusion: We conclude that long-term exposure of colon cancer cells to gefitinib and ZD6474 does not modify their cytotoxic effects but it might have an effect on sensitivity to classical cytotoxic drugs.

Original languageEnglish
Pages (from-to)5140-5147
Number of pages8
JournalWorld Journal of Gastroenterology
Volume12
Issue number32
Publication statusPublished - Aug 28 2006

Keywords

  • Chemo-resistance
  • Colon cancer
  • Gefitinib
  • Tyrosine kinase
  • ZD6474

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Prolonged exposure of colon cancer cell to the epidermal growth factor receptor inhibitor gefitinib (Iressa™) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects'. Together they form a unique fingerprint.

  • Cite this